or Try an Advanced Search...

    Technical Analysis for MXCT - MaxCyte, Inc.

    Grade Last Price % Change Price Change
    F 3.83 -2.30% -0.09
    MXCT closed down 2.3 percent on Monday, July 1, 2024, on 72 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical MXCT trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Volume Surge Other -2.30%
    Wide Bands Range Expansion -2.30%
    Oversold Stochastic Weakness -2.30%
    Narrow Range Bar Range Contraction -4.25%
    Doji - Bullish? Reversal -4.25%
    Oversold Stochastic Weakness -4.25%
    Down 3 Days in a Row Weakness -3.77%
    Lower Bollinger Band Touch Weakness -3.77%
    Older End-of-Day Signals for MXCT ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 6 hours ago
    Down 2 % about 6 hours ago
    Down 1% about 6 hours ago
    Up 1% about 6 hours ago
    Down 1% 3 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MXCT Chart by TradingView
    Basic chart:

    Profile

    MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The company's existing customer base ranges from large biopharmaceutical companies — including 20 of the top 25 pharmaceutical companies based on 2020 global revenue — to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 13 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Pharmacy Cell Therapy Genscript Biotech Synbio

    Is MXCT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 14 President of MaxCyte Maher Masoud Buys More Stock
    Jun 13 Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
    Jun 13 Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
    Jun 11 Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT)
    May 29 MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
    May 23 With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
    May 22 MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
    May 12 MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
    May 11 MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
    May 8 Q1 2024 MaxCyte Inc Earnings Call
    See more MXCT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.545
    52 Week Low 2.45
    Average Volume 565,770
    200-Day Moving Average 4.23
    50-Day Moving Average 4.36
    20-Day Moving Average 4.46
    10-Day Moving Average 4.15
    Average True Range 0.25
    RSI (14) 32.89
    ADX 30.85
    +DI 13.56
    -DI 27.48
    Chandelier Exit (Long, 3 ATRs) 4.52
    Chandelier Exit (Short, 3 ATRs) 4.52
    Upper Bollinger Bands 5.22
    Lower Bollinger Band 3.70
    Percent B (%b) 0.09
    BandWidth 33.99
    MACD Line -0.16
    MACD Signal Line -0.06
    MACD Histogram -0.0995
    Fundamentals Value
    Market Cap 396.7 Million
    Num Shares 104 Million
    EPS -0.37
    Price-to-Earnings (P/E) Ratio -10.35
    Price-to-Sales 13.40
    Price-to-Book 2.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.15
    Resistance 3 (R3) 4.16 4.08 4.09
    Resistance 2 (R2) 4.08 4.00 4.07 4.07
    Resistance 1 (R1) 3.95 3.95 3.91 3.94 4.06
    Pivot Point 3.87 3.87 3.85 3.86 3.87
    Support 1 (S1) 3.74 3.79 3.70 3.73 3.60
    Support 2 (S2) 3.66 3.74 3.65 3.59
    Support 3 (S3) 3.53 3.66 3.57
    Support 4 (S4) 3.52